期刊文献+

CD133在乳腺癌新辅助化疗后的表达及其临床意义 被引量:6

The expression of CD133 in breast cancer after neoadjuvant chemotherapy and its clinical significance
下载PDF
导出
摘要 目的探讨分化抗原簇蛋白133(CD133)表达与新辅助化疗(NAC)化学敏感性的关系。方法对51例原发性乳腺癌患者在NAC治疗前后分别采用免疫组化方法检测CD133表达,观察NAC治疗前后CD133的差异性。结果CD133与病理完全缓解率(pCR)存在明显相关性(P=0.023)。NAC治疗后临床完全缓解率及部分缓解率(cCR+cPR)达到82.4%(42/51),病理反应2级+3级达到54.9%,pCR 31.3%(16/51)。CD133表达与乳腺癌淋巴结转移有关(P=0.042);CD133(+)在pCR方面明显低于CD133(-)(P=0.035);病理1级者较2级或3级更易出现CD133(+)(P=0.002)。CD133(+)在NAC治疗后57.1%(20/41)高于NAC治疗前47.1%(24/51),NAC治疗前后均为CD133(-)与病理反应有效率(2级)呈正相关关系(P<0.001)。同样,经NAC治疗后,8例CD133(+)转为CD133(-),其与病理有效率亦呈正相关关系(P=0.019)。结论 CD133可以作为一种有效标志物来预测NAC治疗乳腺癌的化学敏感性。 Objective To identify CD133 expression by immunohistoehemical staining testing before and after neoadjuvant chemotherapy (NAC) treatment and to diseuss the relationship between chemical sensitivity of CD133 expression and NAC treatment. Methods To observe the difference of CD133 using method to detect CD133 expression with 51 primary breast cancer patients before and after NAC treatment, respeetively. Results CD133 is obviously relevant of pCR ( P = 0. 023 ). The rate of eCR + cPR reached 82.4% (42/51) after NAC treatment. The rate of pathological reaetion level 2 + 3 reaehed 54.9%, pCR31.3% ( 16/51 ). CD133 expression is associated with breast cancer lymph node metastasis ( P =0. 042). The PCR expression in CD133 ( + ) was lower than that of CD133 ( - ) ( P =0. 035 ). Pathologi- eal grade 1 is more likely to appear CD133 ( + ) compared with level 2 or level 3 ( P =0. 002). CD133 ( + ) was 57.1% (20/41) after NAC treatment, which was more than 47.1% (24/51 ) before the NAC treatment. CD133 ( - ) has a positive correlation with pathological reaction effi- eieney ( level 2) ( P 〈 O. 001 ). 8 eases with CD133 ( + ) translated into CD133 ( - ) , whieh also had a positively correlation with pathological efficient ( P = O. 019). Conclusion CD133 can serve as an effective marker to predict the NAC chemical sensitivity for breast cancer patient.
出处 《临床和实验医学杂志》 2014年第4期297-300,共4页 Journal of Clinical and Experimental Medicine
基金 河北省承德市科学技术研究与发展计划项目(编号:20122186)
关键词 乳腺癌 新辅助治疗 CD133 化学敏感性 Breast cancer Neoadjuvant chemotherapy CD133 Chemical sensitivity
  • 相关文献

参考文献18

  • 1Smith IC,Heys SD,Hutcheon AW. Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel[J].J Clin Oncol,2002,(06):1456-1466. 被引量:1
  • 2Charafe-Jauffret E,Ginestier C,Iovino F. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer[J].Clin Cancer Res,2010,(01):45-55. 被引量:1
  • 3Hilbe W,Dirnhofer S,Oberwasserlechner F. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer[J].J Clin Pathol,2004,(09):965-969. 被引量:1
  • 4Wolchok JD,Hoos A,ODay S. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria[J].Clin Cancer Res,2009,(23):7412-7420. 被引量:1
  • 5Kurosumi M,Akashi-Tanaka S,Akiyama F. Histopathological criteria for assessment of therapeutic response in breastcancer (2007 version)[J].Breast Cancer,2008,(01):5-7. 被引量:1
  • 6Mayer EL,Carey LA,Burstein HJ. Clinical trial update:implications and management of residual disease afterneoadjuvant therapy for breast cancer[J].Breast Cancer Res,2007,(05):110. 被引量:1
  • 7Fisher CS,Ma CX,Gillanders WE. Neoadjuvant chemotherapy is associated with improved survival comparedwith adjuvant chemotherapy in patients with triple-negative breast cancer onlyafter complete pathologic response[J].Ann Surg Oncol,2012,(01):253-258. 被引量:1
  • 8Resetkova E,Reis-Filho JS,Jain RK. Prognostic impact of ALDH1 in breast cancer:a story of stem cells and tumormicroenvironment[J].Breast Cancer Res Treat,2010,(01):97-108. 被引量:1
  • 9Fisher CS,Ma CX,Gillanders WE. Neoadjuvant chemotherapy is associated with improved survival comparedwith adjuvant chemotherapy in patients with triple-negative breast canceronly after complete pathologic response[J].Ann Surg Oncol,2012,(01):253-258. 被引量:1
  • 10Chollet P,Amat S,Cure H. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J].Br J Cancer,2002,(07):1041-1046. 被引量:1

二级参考文献10

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2谢芳,邓海贞,顾永平,任苏勤,蒋栋毅,吴德明.星形细胞瘤组织中缺氧诱导因子-1α、VEGF、iNOs的表达及其与MVD的关系[J].临床与实验病理学杂志,2006,22(4):458-460. 被引量:2
  • 3谢芳,邓敏,邓海贞,任苏勤,蒋栋毅,张学光.人脑星形细胞瘤组织中低氧诱导因子1α与p53的生物学意义[J].江苏医药,2007,33(1):3-5. 被引量:3
  • 4Gil J, Stemhalska A, Pesz KA, et al. Cancer stem cells: the theory and perspectives in cancer therapy[J]. J Appl Genet, 2008,49(2) : 193-199. 被引量:1
  • 5Toren A, Bielorai B, Jacob-Hirseh J,et al. CD133-positive hematopoietic stem cell "sternness" genes contain many genes mutated or abnormally expressed in leukemia [J]. Stem Cells, 2005,23 (8) : 1142-1153. 被引量:1
  • 6Tavassoeli FA, Devilee P. Pathology and genetics tumours of the breast and female genital organs[M], Lyom IARC Press, 2003 : 10-20. 被引量:1
  • 7Millikan C, Newman B, Tse CK, et al. Epidemiology of basal- like breast cancer[J]. Breast Cancer Res Treat, 2008, 109 (1):123-139. 被引量:1
  • 8Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer[J]. J Clin Pathol, 2004,57(9) :965-969. 被引量:1
  • 9Zhang M,Song T, Yang L, et al. Nestin and CD133 : valuable stern cell-specific markers for determining clinical outcome of glioma patients[J]. J Exp Clin Cancer Res, 2008,27 (1) : 85-92. 被引量:1
  • 10Xu J, Xu HY, Zhang Q, et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma[J].Mol Cancer Res,2007,5(6) :605-614. 被引量:1

共引文献4

同被引文献67

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部